United Kingdom· GB-APID-44851811000001100
Breyanzi 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vials
A lisocabtagene maraleucel product containing lisocabtagene maraleucel, registered in United Kingdom by Bristol-Myers Squibb Pharmaceuticals Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lisocabtagene maraleucel is registered in 12 of 19 countries.
Countries holding a registration under ATC L01XL08 (lisocabtagene maraleucel), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Lisocabtagene maraleucel · ATC L01XL08
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lisocabtagene maraleucel
- Manufacturer
- Bristol-Myers Squibb Pharmaceuticals Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01XL08
- ATC class
- Lisocabtagene maraleucel
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
37 interactions on record for lisocabtagene maraleucel.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lisocabtagene maraleucel · interactions on record
37 records
- 21 severe
- 16 moderate
Most severe, free to view
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- NatalizumabL04AA23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lisocabtagene maraleucel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBreyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectieCelgene Europe B.V.
- CanadaBREYANZIBRISTOL-MYERS SQUIBB CANADA
- CzechiaBREYANZIBristol-Myers Squibb Pharma EEIG, Dublin
- SpainBREYANZI 1,1-70 × 10E6 CELULAS/ML / 1,1-70 × 10E6 CELULAS/ML DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandBreyanziBristol-Myers Squibb Pharma EEIG
- FranceBREYANZI 1,1 à 70 × 1 000 000 cellules/ml / 1,1 à 70 × 1 000 000 cellules/ml, dispersion pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- IrelandBreyanzi 1.1-70 x 10^6 cells/mL/1.1-70 x 10^6 cells/mL dispersion for infusionCelgene Europe B.V.
- IcelandBreyanziBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Breyanzi
- Liechtenstein · Breyanzi
- Norway · Breyanzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/363d9dfc-12a5-4f0a-8414-02e9131ba3cd GET /v1/drugs/363d9dfc-12a5-4f0a-8414-02e9131ba3cd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "44851811000001100",
"desc": "Breyanzi 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vials (Bristol-Myers Squibb Pharmaceuticals Ltd)",
"form": "Dispersion for infusion",
"vpid": "44881811000001105",
"source": "dmd",
"vtm_id": "1148951001",
"strength": null,
"substance": "Lisocabtagene maraleucel",
"ingredient": "Lisocabtagene maraleucel",
"supplier_code": "3145301000001104"
}See everything about lisocabtagene maraleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.